当前位置: X-MOL 学术Epilepsy Curr. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019.
Epilepsy Currents ( IF 5.8 ) Pub Date : 2019-10-22 , DOI: 10.1177/1535759719878716
Timothy E Welty 1 , Kevin E Chapman 2 , R Edward Faught 3 , Robert J Kotloski 4
Affiliation  

On April 3, 2019, the US Food and Drug Administration (FDA) announced a public hearing on May 31, 2019 and a call for written comments on the topic of cannabis and cannabis-derived compounds.1 Kevin Chapman, MD, spoke on behalf of the American Epilepsy Society (AES) at the public hearing. Transcripts of comments, including those by Dr Chapman, are available through the FDA website.2

中文翻译:


美国癫痫协会 (AES):给美国食品和药物管理局 (FDA) 卫生与公众服务部 (HHS) 食品和药物代理专员 Norman E.“Ned”Sharpless 医学博士的书面评论:案卷 ID# FDA-2019-N-1482,有关含有大麻或大麻衍生化合物的产品的科学数据和信息;公开听证会;征求意见:提交日期:2019 年 7 月 16 日。



2019年4月3日,美国食品药品监督管理局(FDA)宣布于2019年5月31日举行公开听证会,并呼吁就大麻和大麻衍生化合物的主题提供书面评论。 1 Kevin Chapman 医学博士代表美国癫痫协会 (AES) 在公开听证会上发言。评论文字记录,包括查普曼博士的评论文字记录,可通过 FDA 网站获取。 2
更新日期:2019-10-22
down
wechat
bug